Cite
Frezzato F, Visentin A, Severin F, et al. Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia. Cancers (Basel). 2021;13(21)doi: 10.3390/cancers13215453.
Frezzato, F., Visentin, A., Severin, F., Pizzo, S., Ruggeri, E., Mouawad, N., Martinello, L., Pagnin, E., Trimarco, V., Tonini, A., Carraro, S., Pravato, S., Imbergamo, S., Manni, S., Piazza, F., Brunati, A. M., Facco, M., & Trentin, L. (2021). Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia. Cancers, 13(21), . https://doi.org/10.3390/cancers13215453
Frezzato, Federica, et al. "Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia." Cancers vol. 13,21 (2021). doi: https://doi.org/10.3390/cancers13215453
Frezzato F, Visentin A, Severin F, Pizzo S, Ruggeri E, Mouawad N, Martinello L, Pagnin E, Trimarco V, Tonini A, Carraro S, Pravato S, Imbergamo S, Manni S, Piazza F, Brunati AM, Facco M, Trentin L. Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia. Cancers (Basel). 2021 Oct 29;13(21). doi: 10.3390/cancers13215453. PMID: 34771616; PMCID: PMC8582437.
Copy
Download .nbib